Marksans Pharma Limited

NSEI:MARKSANS Stok Raporu

Piyasa değeri: ₹139.9b

Marksans Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mark Saldanha

İcra Kurulu Başkanı

₹68.9m

Toplam tazminat

CEO maaş yüzdesi69.7%
CEO görev süresi9.1yrs
CEO sahipliği43.8%
Yönetim ortalama görev süresi13yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

CEO Tazminat Analizi

Mark Saldanha'un ücretlendirmesi Marksans Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹69m₹48m

₹3b

Dec 31 2023n/an/a

₹3b

Sep 30 2023n/an/a

₹3b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹52m₹48m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹38m₹35m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹3b

Mar 31 2021₹10m₹10m

₹2b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹10m₹10m

₹1b

Dec 31 2019n/an/a

₹879m

Sep 30 2019n/an/a

₹834m

Jun 30 2019n/an/a

₹780m

Mar 31 2019₹10m₹10m

₹804m

Dec 31 2018n/an/a

₹666m

Sep 30 2018n/an/a

₹582m

Jun 30 2018n/an/a

₹463m

Mar 31 2018₹12m₹10m

₹358m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 815.41K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 481.61K ).

Tazminat ve Kazançlar: Mark 'in maaşı son bir yılda %20'den fazla arttı.


CEO

Mark Saldanha (52 yo)

9.1yrs

Görev süresi

₹68,857,053

Tazminat

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mark Saldanha
Non-Independent Executive Chairman & MDno data₹68.86m43.8%
₹ 61.3b
Jitendra Sharma
Chief Financial Officer22.2yrs₹12.84mVeri yok
Vishal Bhargava
Director Operationsno data₹5.80mVeri yok
Harshavardhan Panigrahi
Company Secretary15.8yrs₹2.84mVeri yok
Sandra Saldanha
Whole-Time Executive Non Independent Director10.2yrs₹7.07m0.073%
₹ 102.0m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75mVeri yok
Sunil Rane
Senior Vice President of QCno data₹10.61mVeri yok
David Mohammed
Managing Director of Australia Operationsno dataVeri yokVeri yok
Sathish Kumar
Managing Director of UK Operationsno dataVeri yokVeri yok
Anjani Kumar
Chief Operating Officer of US Operationsno data₹10.29mVeri yok

13.0yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: MARKSANS 'un yönetim ekibi deneyimli ve deneyimlidir ( 13 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mark Saldanha
Non-Independent Executive Chairman & MD9.1yrs₹68.86m43.8%
₹ 61.3b
Sandra Saldanha
Whole-Time Executive Non Independent Director10.2yrs₹7.07m0.073%
₹ 102.0m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75mVeri yok
Sunny Sharma
Non-Executive & Non-Independent Director3.3yrsVeri yokVeri yok
Abhinna Mohanty
Non-Executive & Independent Director5.3yrs₹15.00kVeri yok
Shailaja Vardhan
Non-Executive & Independent Director1.5yrs₹300.00kVeri yok
Seetharama Buddharaju
Non-Executive & Independent Director13.1yrs₹25.00kVeri yok
Digant Parikh
Non-Executive Independent Director6.7yrs₹400.00kVeri yok

6.3yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MARKSANS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).